Chinook Therapeutics Announces Upcoming Data Presentations and Investor Conference Call During the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined
- Presentations on atrasentan and BION-1301 clinical programs for the treatment of IgA Nephropathy
- First presentation on CHK-336, a novel oral small molecule lactate dehydrogenase (LDH) inhibitor for the treatment of primary hyperoxaluria; Phase 1 initiation planned for H2 2021
- Chinook to host investor conference call and webcast on October 22, 2020 to review abstracts and provide updates on the company’s pipeline
|Abstract SA-OR21||Single Cell Transcriptomic Analysis to Define Cellular Heterogeneity in Human ADPKD|
|Session:||Kidneyomics: From Cysts to Populations|
|Abstract INFO29||Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atrasentan in Patients with IgA Nephropathy (The ALIGN Study)|
|Abstract PO1843||Results of a Phase 1 Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in
|Abstract PO1620||Discovery of CHK-336: A First-in-Class, Liver-Targeted, Small Molecule Inhibitor of Lactate Dehydrogenase for the Treatment of Primary Hyperoxaluria|
Conference Call Details
To access the call, please dial (844) 309-0604 (domestic) or (574) 990-9932 (international) and provide the Conference ID 5981714 to the operator.
To access the live webcast and subsequent archived recording of this and other company presentations, please visit the investors section of Chinook’s website at www.chinooktx.com. The archived webcast will remain available for replay on Chinook’s website for 90 days.
Cautionary Note on Forward-Looking Statements
Certain of the statements made in this press release are forward looking, including those relating to Chinook’s business, future operations, advancement of its product candidates and product pipeline, clinical development of its product candidates, including expectations regarding timing of initiation and results of clinical trials. In some cases, you can identify these statements by forward-looking words such as “may,” “will,” “continue,” “anticipate,” “intend,” “could,” “project,” “expect” or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, whether results of early clinical trials or preclinical studies will be indicative of the results of future trials, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that may be more advanced or have greater resources than we do, our ability to obtain and adequately protect intellectual property rights for our product candidates and the effects of COVID-19 on our clinical programs and business operations. Many of these risks are described in greater detail in our filings with the
Source: Chinook Therapeutics, Inc.